Search
for

    GlossaryJuvederm

    injectable filler made from hyaluronic acid for cosmetic use

    Juvederm is a brand of injectable dermal fillers made from hyaluronic acid, a substance naturally found in the skin. It is commonly used in cosmetic procedures to reduce the appearance of wrinkles, add volume to facial tissues, and enhance lips. The effects are temporary, typically lasting from six months to a year, depending on the specific product and treatment area.

    Related Terms

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results

      community Tropoelastin injections + verteporfin?

      in Research/Science  12 upvotes 3 years ago
      The use of tropoelastin injections and verteporfin for hair transplant recipients to help regrow donor area hairs, as well as research done on tropoelastin injections restoring elastin in scarred heart tissue and skin. There are discussions about why it is taking so long to get cosmetic mass produced tropoelastin injectables on the market.

      community I’m taking Veradermics VDPHL01 - AMA

      in Treatment  174 upvotes 1 month ago
      A participant using Veradermics VDPHL01, an extended-release oral minoxidil, experienced significant hair regrowth from Norwood 6 to Norwood 3V without side effects. They plan to use dutasteride after the treatment to maintain results.

      community Verteporfin (Visudyne) group buy 🌷

      in Treatment  29 upvotes 4 years ago
      User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.

      community Very exited about Veradermics,

      in Research/Science  29 upvotes 1 month ago
      Veradermics is a promising new treatment for hair loss, essentially a repackaged version of Minoxidil. The user is optimistic about its potential effectiveness.

      community Veradermics VDPHL01: why isn’t anyone talking about it?

      in Treatment  42 upvotes 1 year ago
      Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.